A ‘combination formulation’ refers to a pharmaceutical formulation containing two or more active ingredients. Leveraging synergistic effects, a combination formulation often exhibits better efficacy ...

The FDA has approved George Medicines’ Widaplik (telmisartan, amlodipine, and indapamide), a novel single-pill triple combination therapy for hypertension in adults, including for initial treatment.

A new era of hypertension treatment is on the horizon for U.S. | The drug is the first triple-combo pill for the initial treatment of hypertension in the U.S.

The U.S. Food and Drug Administration has approved George Medicines' Widaplik (telmisartan, amlodipine, and indapamide) for the treatment of hypertension in adults. The combination pill is the ...

The patients were given a combination of the current standard of care, azacitidine and venetoclax, two established chemotherapy drugs, with revumenib. The overall response rate, defined as no ...

GSK’s Blenrep (belantamab mafodotin) has been recommended by the National Institute for Health and Care Excellence (NICE) as part of a combination treatment for multiple myeloma (MM). The health ...

The FDA has approved a new pill called Widaplik, which combines three drugs – telmisartan, amlodipine, and indapamide – to treat adults who have high blood pressure.

Zepzelca-Tecentriq combo significantly extends survival in extended stage small cell lung cancer (ES-SCLC): The IMforte Phase III trial showed that Jazz's Zepzelca plus Tecentriq nearly doubled ...

Amlodipine is characterised by a long elimination half-life of 35–50 hours, a bioavailability of 64–80%, and peak plasma concentrations after 6–12 hours. [1] ...

Board combines global leadership experience with backgrounds in energy, aviation, finance, and private equityDirectors offer deep expertise in scaling businesses, managing public companies, and ...

The cardiovascular disease continuum. CAD=coronary artery disease; CHF=congestive heart failure. Reprinted with permission from Am Heart J. 1991;121:1244 1263. [2] ...